MedTrace Logo

Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer

NCT00111618 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2009-01-30

No results posted yet for this study

Summary

The purpose of this trial is to confirm a safe dose of AS1404, to be given with docetaxel, and to see whether adding AS1404 and docetaxel together improves the outcome of the treatment, when compared to docetaxel alone.

Conditions

Interventions

DRUG

AS1404 (DMXAA)

Sponsors & Collaborators

  • Antisoma Research

    lead INDUSTRY

Principal Investigators

  • Roberto Pili, MD · The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2007-06-30
Completion
2008-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00111618 on ClinicalTrials.gov